• 대한화장품학회지
• /
• 제39권2호
• /
• pp.133-140
• /
• 2013

항균비누에 흔히 사용되는 항균성분인 PCMX와 IPMP에 대하여 ASTM E2752-10 (Standard Guide for Evaluation of Residual Effectiveness of Anti- bacterial Personal Cleansing Products)에 기술된 cup scrub method에 따라 항균 지속력을 평가하였다. 건강한 남녀 총 80명의 피험자를 대상으로 한 실험에서 5% PCMX와 0.1% IPMP를 함유한 액체비누는 대조군에 비해서 E. coli와 S. aureus의 수를 통계학적으로 유의하게 감소시켰으며 27시간 동안 항균효과가 지속되는 것을 확인하였다. 항균성분의 지속력에 대한 인체적용 시험은 국내에서는 처음 시행된 것으로 결과와 함께 보고하는 바이다.

• Biomolecules & Therapeutics
• /
• 제7권1호
• /
• pp.44-53
• /
• 1999

The resistant strains due to the extended-spectrum $\beta$-lactamase (ESBL) were susceptible to cefatrizine combined with clavulanic acid. The purpose of this study was to evaluate the in vitro and in vivo antibacterial activities of cefatrizine/clavulanic acid (CTRZ/CV) combination at a ratio of 2 : 1 in comparison with cefaclor (CCLO), cefuroxime (CRXM), cefuroxime axetil (CRXMA) and amoxicillin/clavulanic acid (AMXCCV). CTRZ/CV showed good activity against laboratory strains of gram-positive and gram-negative bacteria and exhibited excellent antibacterial activity against $\beta$-lactamase-producing strains. The bactericidal activity of CTRZ/CV was superior to that of CCLO and CRXM, and almost equal to that of AMXCCV against the $\beta$-lactamase-producing strains. The in vitro results were substantiated. by in vivo mouse experimental infection studies with $\beta$-lactamase-producing and non-producing strains. In mixed experimental infection due to $\beta$-lactamase-producing and non-producing strains, the therapeutic efficacy of CTRZ/CV was superior to that of CTRZ, CCLO, CRXMA and AMXCCV. In respiratory tract infection in mice due to Klebsiella pneumoniae EB4O, CTRZ/CV was more erective than CCLO, CRXMA and AMXCCV and also more efficacious than CCLO, CRXMA and AMXCCV in urinary tract infection in mice due to Escherichia coli EB13. These results indicate that CTRZ/CV is a useful drug for the treatment of infection caused by $\beta$-1actamase-producing strains including ESBL-producing strains.

• 한국포장학회지
• /
• 제30권1호
• /
• pp.15-21
• /
• 2024

The edible coating system, consisting of gelatin and bacteriophages, has been developed to enhance the microbial safety of wild vegetables. Newly isolated Escherichia coli phage EP and Staphylococcus aureus phage SP were loaded into the gelatin coating solutions. The phages remained significantly stable for up to 3 days, respectively, and exhibited rapid antibacterial capacity within 2 h of coating application (p < 0.05). The developed coating was applied to bracken and exhibited antibacterial efficacy against E. coli and S. aureus within 6 h (1.9-log CFU/mL and 1.5-log CFU/mL). Furthermore, the coated bracken significantly prevented weight loss and maintained firmness for 10 days (p < 0.05). Consequently, gelatin-based edible coatings containing phages have the potential as an antibacterial packaging strategy.

• 대한화장품학회지
• /
• 제46권2호
• /
• pp.159-166
• /
• 2020

프로폴리스는 식물에서 채취한 수지에 꿀벌의 분비물이 합쳐져 만들어진 아교성 물질로 세균이나 바이러스로부터 자신을 보호하는 기능을 한다. 본 연구에서는 한국, 중국, 브라질 유래 프로폴리스 추출물의 항산화, 항균, 미백, 항염 활성을 비교하고, 이들 추출물의 화장품소재로서의 응용가능성을 살펴보았다. 플라보노이드, 폴리페놀함량분석과 자유라디칼 소거능 시험을 통해 항산화 활성을 확인한 결과 한국, 중국, 브라질 프로폴리스 추출물 모두 유의한 항산화 효능을 보였다. 피부에 상재하는 미생물에 대한 항균효능을 MIC 시험법을 통해 측정한 결과 C. acnes 균에서 한국 프로폴리스 추출물이 다른 추출물에 비해 우수한 항균력을 보였다(KPE: 62.5 ㎍/mL, CPE: 250 ㎍/mL, BPE: 500 ㎍/mL). 또한, 한국 프로폴리스 추출물은 멜라닌 세포의 멜라닌 생성을 억제하였고, 마우스대식세포에서 리포폴리사카라이드로 유도된 염증인자인 산화질소와 PGE₂ 생성을 나머지 두 추출물보다 우수하게 억제하였다. 이들 결과를 종합하면 프로폴리스 추출물은 항산화, 항균, 항염 효능소재로 응용될 수 있으며, 특히 항균, 항염, 미백에서 우수한 효능을 보인 한국프로폴리스추출물의 응용가능성이 우수함을 확인할 수 있었다.

• Journal of Microbiology and Biotechnology
• /
• 제31권12호
• /
• pp.1656-1666
• /
• 2021

Dental pathogens lead to chronic diseases like periodontitis, which causes loss of teeth. Here, we examined the plausible antibacterial efficacy of copper nanoparticles (CuNPs) synthesized using Cupressus macrocarpa extract (CME) against periodontitis-causing bacteria. The antimicrobial properties of CME-CuNPs were then assessed against oral microbes (M. luteus. B. subtilis, P. aerioginosa) that cause periodontal disease and were identified using morphological/ biochemical analysis, and 16S-rRNA techniques. The CME-CuNPs were characterized, and accordingly, the peak found at 577 nm using UV-Vis spectrometer showed the formation of stable CME-CuNPs. Also, the results revealed the formation of spherical and oblong monodispersed CME-CuNPs with sizes ranged from 11.3 to 22.4 nm. The FTIR analysis suggested that the CME contains reducing agents that consequently had a role in Cu reduction and CME-CuNP formation. Furthermore, the CME-CuNPs exhibited potent antimicrobial efficacy against different isolates which was superior to the reported values in literature. The antibacterial efficacy of CME-CuNPs on oral bacteria was compared to the synergistic solution of clindamycin with CME-CuNPs. The solution exhibited a superior capacity to prevent bacterial growth. Minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and fractional inhibitory concentration (FIC) of CME-CuNPs with clindamycin recorded against the selected periodontal disease-causing microorganisms were observed between the range of 2.6-3.6 ㎍/ml, 4-5 ㎍/ml and 0.312-0.5, respectively. Finally, the synergistic antimicrobial efficacy exhibited by CME-CuNPs with clindamycin against the tested strains could be useful for the future development of more effective treatments to control dental diseases.

• Journal of Microbiology and Biotechnology
• /
• 제34권8호
• /
• pp.1718-1726
• /
• 2024

Development of novel antibacterial agents is imperative due to the increasing threat of antibiotic-resistant pathogens. This study aimed to develop the enhanced antibacterial activity and in-vivo efficacy of a novel truncated endolysin, CHAP^SAP26-161, derived from the endolysin Lys^SAP26, against multidrug-resistant bacteria. CHAP^SAP26-161 exhibited higher protein purification efficiency in E. coli and antibacterial activity than Lys^SAP26. Moreover, CHAP^SAP26-161 showed the higher lytic activity against A. baumannii with minimal bactericidal concentrations (MBCs) of 5-10 ㎍/ml, followed by Staphylococcus aureus with MBCs of 10-25 ㎍/ml. Interestingly, CHAP^SAP26-161 could lyse anaerobic bacteria, such as Clostridioides difficile, with MBCs of 25-50 ㎍/ml. At pH 4-8 and temperatures of 4℃-45℃, CHAP^SAP26-161 maintained antibacterial activity without remarkable difference. The lytic activity of CHAP^SAP26-161 was increased with Zn²⁺. In vivo tests demonstrated the therapeutic effects of CHAP^SAP26-161 in murine systemic A. baumannii infection model. In conclusion, CHAP^SAP26-161, a truncated endolysin that retains only the CHAP domain from Lys^SAP26, demonstrated enhanced protein purification efficiency and antibacterial activity compared to Lys^SAP26. It further displayed broad-spectrum antibacterial effects against S. aureus, A. baumannii, and C. difficile. Our in vitro and in-vivo results of CHAP^SAP26-161 highlights its promise as an innovative therapeutic option against those bacteria with multiple antibiotic resistance.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1997년도 춘계학술대회
• /
• pp.40-47
• /
• 1997

New quinolones generally have a broad antibacterial spectrum against gram-positive, gram-negative, glucose-nonfermenting and anaerobic bacteria. Some of newly developed quinolones have potent activities against S. aureus including MRSA, S.pneumoniae including PRSP, B. fragilis, chlamydiae, mycoplasmas and mycobacteria as well, and show good activities against various strains resistant to antibacterial agents of other classes. Quinolones display postantibiotic effects in vitro and are bactericidal at concentrations similar to or twice that of the minimum inhibitory concentrations (MICs) for susceptible pathogens. In experimental murine infection models including systemic infections with various pathogens such as S. aureus, S. pyogenes, S. pneumoniae, E. coli and P. aeruginosa, quinolones have shown good oral efficacy as well as parenteral efficacy. Good oral absorption and good tissue penetration of quinolones account for good therapeutic effects in clinical settings. The target of quinolones are two structurally related type II topoisomerases, DNA gyrase and DNA topoisomerase IV. Quinolones are shown to stabilize the ternary quinolone-gyrase-DNA complex and inhibit the religation of the cleaved double-stranded DNA. Bacteria can acquire resistance to quinolones by mutations of these target enzymes. Mutation sites and amino acid changes in DNA gyrase and DNA topoisomerase IV are similar in the organisms examined, suggesting that the mechanism of quinolone resistance in the target enzymes is essentially the same among various organisms. Quinolones act on both the target enzymes to different degrees depending on the organisms or agents tested, and bacteria become highly resistant to quinolones in a step-wise fashion. Incomplete cross-resistance among quinolones in some strains of E. coli and S. aureus suggests the possibility of finding quinolones active against quinolone-resistant strains which are prevailing now. To find such quinolones, the potency toward two target enzymes and the membrane permeability including influx and/or efflux systems should be taken into account.

• Restorative Dentistry and Endodontics
• /
• 제45권2호
• /
• pp.23.1-23.12
• /
• 2020

Objectives: This study aimed to summarize the outcome of in vitro studies comparing the antibacterial effectiveness of QMix with other irrigants against Enterococcus faecalis. Materials and Methods: The research question was developed by using population, intervention, comparison, outcome, and study design framework. The literature search was performed using 3 electronic databases: PubMed, Scopus, and EBSCOhost until October 2019. The additional hand search was performed from the reference list of the eligible studies. The risk of bias of the studies was independently appraised using the revised Cochrane Risk of Bias tool (RoB 2.0). Results: Fourteen studies were included in this systematic review. The overall risk of bias for the selected studies was moderate. QMix was found to have a higher antimicrobial activity compared to 2% sodium hypochlorite (NaOCl), 17% ethylenediaminetetraacetic acid (EDTA), 2% chlorhexidine (CHX), mixture of tetracycline isonomer, an acid and a detergent (MTAD), 0.2% Cetrimide, SilverSol/H2O2, HYBENX, and grape seed extract (GSE). QMix had higher antibacterial efficacy compared to NaOCl, only when used for a longer time (10 minutes) and with higher volume (above 3 mL). Conclusions: QMix has higher antibacterial activity than 17% EDTA, 2% CHX, MTAD, 0.2% Cetrimide, SilverSol/H2O2, HYBENX, GSE and NaOCl with lower concentration. To improve the effectiveness, QMix is to use for a longer time and at a higher volume.

• 융합정보논문지
• /
• 제11권6호
• /
• pp.206-212
• /
• 2021

본 연구는 참당귀에서 유효 성분을 보다 효율적으로 추출하는 방법을 찾아 참당귀의 효능을 극대화하는 것을 목표로 하였다. 열수, 에탄올 및 초임계 이산화탄소 추출법으로 참당귀를 추출한 후, 데커신, 데커시놀 안젤레이트 함량 분석, 총 폴리페놀 함량 정량, 그리고 항산화, 미백, 항균에 대한 효능 평가를 진행하였다. 데커신, 데커시놀 안젤레이트의 함량은 초임계 이산화탄소 추출물에서 38.65%로 매우 높았고, 총 폴리페놀 함량은 열수 추출물, 에탄올 추출물, 초임계 이산화탄소 추출물 순으로 높았지만, 그 차이가 비교적 적었다. 항산화 효능은 총 폴리페놀 함량과 경향이 일치하였고, 항균 효능은 데커신, 데커시놀 안젤레이트 함량과 경향이 일치하였다. 본 연구를 통해 참당귀에서 유효 성분을 추출하기 위한 최적의 방법은 초임계 이산화탄소 추출법임을 확인하였다.

• 대한한의학방제학회지
• /
• 제7권1호
• /
• pp.65-76
• /
• 1999

According to the study of literature on RADIX STEMONAE about its efficacy, pharmacological action, and clinical adaptive disease, the results are as follows; 1. About the efficacy of RADIX STEMONAE, it is known as moistening the lungs to arrest cough, and intestinal parasites from ancient to now, and dispelling phlegm is also known. 2. The clinical adaptation of RADIX STEMONAE is chronic bronchitis, pertussis, pulmonary tuberculosis in respiratory disease, and ascaricide for Ascaris, Enterobius vermicularis or eczema, pruritus, destroy louse for endermic liniment. 3. The pharmacological action of RADIX STEMONAE are antitussive, tuberculostatic, anthelmintic, antibacterial, antivirus, antifungal. 4. The antitussive mechanism of RADIX STEMONAE is central inhibitor for cough center of medulla oblongata, and the mechanisms of bronchial smooth muscle relax, and expectorant is also known.